Sopharma AD (SPH.WA)
PLN 12.8
(6.22%)
PLN 12.8
(6.22%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 177.28 Million BGN | 10.96% |
| 2022 | 143.19 Million BGN | 12.45% |
| 2021 | 142.73 Million BGN | 44.43% |
| 2020 | 90.48 Million BGN | -34.59% |
| 2019 | 143.87 Million BGN | 86.27% |
| 2018 | 76.16 Million BGN | -10.82% |
| 2017 | 90.16 Million BGN | -3.66% |
| 2016 | 100.93 Million BGN | 40.65% |
| 2015 | 63.17 Million BGN | -4.24% |
| 2014 | 70.1 Million BGN | -23.91% |
| 2013 | 92.13 Million BGN | 16.28% |
| 2012 | 72.61 Million BGN | -0.5% |
| 2011 | 73.33 Million BGN | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 51.62 Million BGN | 27.37% |
| 2024 Q2 | 33.89 Million BGN | -19.38% |
| 2023 Q4 | 40.89 Million BGN | 19.59% |
| 2023 FY | - BGN | 10.96% |
| 2023 Q3 | 34.19 Million BGN | -31.52% |
| 2023 Q1 | 53.06 Million BGN | 68.35% |
| 2023 Q2 | 49.93 Million BGN | -5.89% |
| 2022 Q2 | 41.3 Million BGN | 3.85% |
| 2022 Q3 | 47.9 Million BGN | 15.99% |
| 2022 Q4 | 31.52 Million BGN | -34.2% |
| 2022 Q1 | 39.77 Million BGN | 21.03% |
| 2022 FY | - BGN | 12.45% |
| 2021 Q3 | 41.3 Million BGN | 32.13% |
| 2021 Q4 | 32.86 Million BGN | -20.44% |
| 2021 FY | - BGN | 44.43% |
| 2021 Q1 | 37.31 Million BGN | 14.64% |
| 2021 Q2 | 31.25 Million BGN | -16.23% |
| 2020 Q2 | 19.9 Million BGN | -29.01% |
| 2020 FY | - BGN | -34.59% |
| 2020 Q4 | 32.54 Million BGN | 107.26% |
| 2020 Q3 | 15.7 Million BGN | -21.09% |
| 2020 Q1 | 28.03 Million BGN | -61.16% |
| 2019 Q2 | 21.8 Million BGN | -33.15% |
| 2019 Q4 | 72.17 Million BGN | 194.75% |
| 2019 FY | - BGN | 86.27% |
| 2019 Q1 | 32.62 Million BGN | 72.05% |
| 2019 Q3 | 24.48 Million BGN | 12.29% |
| 2018 Q2 | 19.82 Million BGN | -23.09% |
| 2018 FY | - BGN | -10.82% |
| 2018 Q1 | 25.77 Million BGN | 7.58% |
| 2018 Q3 | 16.55 Million BGN | -16.48% |
| 2018 Q4 | 18.96 Million BGN | 14.51% |
| 2017 Q1 | 30.46 Million BGN | -22.76% |
| 2017 Q3 | 16.26 Million BGN | -19.77% |
| 2017 Q4 | 23.95 Million BGN | 47.31% |
| 2017 FY | - BGN | -3.66% |
| 2017 Q2 | 20.27 Million BGN | -33.47% |
| 2016 Q2 | 15.45 Million BGN | -28.48% |
| 2016 FY | - BGN | 40.65% |
| 2016 Q1 | 21.61 Million BGN | 30.18% |
| 2016 Q4 | 39.44 Million BGN | 120.33% |
| 2016 Q3 | 17.9 Million BGN | 15.84% |
| 2015 FY | - BGN | -4.24% |
| 2015 Q4 | 16.6 Million BGN | 99.23% |
| 2015 Q3 | 8.33 Million BGN | -60.24% |
| 2015 Q2 | 20.95 Million BGN | -1.33% |
| 2015 Q1 | 21.24 Million BGN | 45.8% |
| 2014 Q4 | 14.56 Million BGN | 8.32% |
| 2014 FY | - BGN | -23.91% |
| 2014 Q1 | 24.77 Million BGN | -13.49% |
| 2014 Q2 | 17.31 Million BGN | -30.08% |
| 2014 Q3 | 13.44 Million BGN | -22.35% |
| 2013 Q3 | 12.65 Million BGN | -41.01% |
| 2013 Q4 | 28.63 Million BGN | 126.24% |
| 2013 FY | - BGN | 16.28% |
| 2013 Q1 | 29.39 Million BGN | 67.14% |
| 2013 Q2 | 21.45 Million BGN | -27.0% |
| 2012 Q1 | 20.42 Million BGN | 0.0% |
| 2012 FY | - BGN | -0.5% |
| 2012 Q3 | 19.6 Million BGN | -9.32% |
| 2012 Q4 | 17.58 Million BGN | -10.3% |
| 2012 Q2 | 21.62 Million BGN | 5.84% |
| 2011 FY | - BGN | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|